The most common question since July has a frustrating answer: nobody knows, and anyone who gives you a date is guessing.
What can be described precisely is the process. Federal rulemaking has defined stages, and knowing which stage we are in tells you far more than any prediction. Right now we are at the beginning of stage two of five.
The five stages
| Stage | What happens | Status |
|---|---|---|
| 1. Advisory review | PCAC evaluates evidence and votes on a recommendation | Complete — July 24, 2026 |
| 2. Agency deliberation | FDA decides whether to accept, modify or reject the recommendation | In progress |
| 3. Proposed rule | FDA publishes a notice of proposed rulemaking in the Federal Register | Not started |
| 4. Public comment | Comment period opens; agency reviews and responds to submissions | Not started |
| 5. Final rule | Final rule published; substance formally added to the 503A Bulks List | Not started |
Legal compounding under Section 503A becomes possible at stage five. Not before.
Stage two: where we actually are
The FDA is currently reviewing six recommendations that its own scientific staff argued against. That is an unusual position and it is the main reason this stage is hard to time.
The agency has three options. It can accept the recommendations and move toward rulemaking. It can modify them — for instance, by narrowing permitted indications, imposing sourcing requirements, or restricting formulations. Or it can decline to act, which functionally means the recommendations sit indefinitely.
One data point cuts in favor of action: FDA staff noted during the July meeting that the agency rarely diverges from PCAC recommendations. One cuts the other way: the review division opposed all seven nominations on the record.
Why conditions are likely
Several committee members who voted yes attached conditions — authorized API sourcing, adverse-event reporting requirements, formulation limits. Those conditions are not binding, but they map closely onto the objections FDA scientists raised. If a rule emerges, expect it to carry constraints rather than open access.
Stages three through five: the rulemaking machinery
Notice-and-comment rulemaking is deliberate by design. The agency publishes a proposed rule, invites public comment, must consider and respond to substantive submissions, and then issues a final rule. For a contested subject with an active industry and organized opposition on both sides, none of those steps is fast.
Observers expect a proposed rule could appear in late 2026 or during 2027. The complete process could extend well beyond that — a multi-year timeline is a realistic scenario, not a pessimistic one.
Comments still matter
FDA indicated during the meetings that it would consider information received even after the PCAC submission deadlines. Comments addressing safety data, adverse-event reporting and characterization of peptide identity and purity are likely to carry the most weight, because those are the areas where agency scientists raised objections. Anyone with a commercial or clinical stake — pharmacies, telehealth platforms, manufacturers, patient groups — can participate through the docket.
The shortcut nobody should count on
There is a faster path, and it is widely discussed: the FDA could place the recommended peptides in Category 1 on an interim basis, or otherwise signal enforcement discretion while rulemaking proceeds.
Category 1 substances are subject to enforcement discretion and may be used in compounding even though they are not technically on the official list. If the agency took that step, practical access would change in weeks rather than years.
Interim status and formal listing are not the same thing
Category 1 reflects an interim enforcement posture — a statement about how the agency intends to use its discretion. Formal listing provides a definitive legal basis for compounding. An interim signal can be narrowed or withdrawn; a final rule cannot, absent further rulemaking. Treat any enforcement-discretion announcement as provisional.
As of August 12, 2026, no interim reclassification has been announced. It is a plausible scenario, not a current fact.
What would have to be true for compounding to be lawful
Section 503A permits a bulk drug substance only if it has a USP or NF monograph, is a component of an FDA-approved drug product, or appears on the 503A Bulks List. The six recommended peptides satisfy none of the three today.
So the practical checklist is short. Either the FDA completes rulemaking and adds them to the list, or it signals enforcement discretion in the interim. Absent one of those, a pharmacy compounding these substances is outside the statutory conditions regardless of how the July vote went.
The state layer nobody should skip
Even a completed federal rule would not settle the question everywhere. State boards of pharmacy have broad independent authority over compounding in their jurisdictions, and state regimes frequently reference or incorporate federal requirements while adding their own.
Ohio's Board of Pharmacy has issued guidance stating that Category 2 and Category 3 peptides cannot be compounded, and has enforced it — including summary suspension in some cases — against pharmacies working with substances such as BPC-157 and CJC-1295/ipamorelin. How individual state boards respond to a federal rule change is genuinely unsettled, and a stricter state standard would still govern practice in that state.
How to track this yourself
- The Federal Register is the authoritative venue. A proposed rule appears there first, and its publication is the single most meaningful milestone to watch for.
- The FDA docket (FDA-2026-N-2979 for the July meeting) carries meeting materials and public submissions.
- Your state board of pharmacy publishes guidance and disciplinary actions that often move before federal policy does.
- The February 2027 PCAC meeting will be announced with its own docket and will indicate how the agency is handling the first round.
The honest timeline
- Now: FDA deliberating. No legal change.
- Late 2026–2027: a proposed rule could publish. Watch the Federal Register.
- After that: comment period, agency response, final rule. Months at minimum.
- Wildcard: interim Category 1 or enforcement discretion could shortcut the wait. Not announced.
- Throughout: state boards may be stricter, and a federal rule would not override them.
Common questions
No date exists. It requires either completed notice-and-comment rulemaking adding it to the 503A Bulks List, or an FDA signal of interim enforcement discretion. Neither has happened. Estimates for a proposed rule center on late 2026 to 2027, with the full process potentially running longer.
The standard federal process for issuing a regulation: the agency publishes a proposed rule, opens a public comment period, considers and responds to substantive comments, then publishes a final rule. It exists to make regulation deliberate and reviewable, which is also why it is slow.
Yes. PCAC advice is non-binding and the agency may accept, modify or reject it. Its own scientists opposed all seven nominations, so rejection or significant modification is a live possibility — though FDA staff noted the agency rarely departs from committee recommendations.
Category 1 substances are subject to enforcement discretion and may be used in compounding even without formal listing. Interim placement would meaningfully open access before rulemaking concludes. It is also reversible in a way a final rule is not.
Yes. Dockets are open to the public. Comments on safety data, adverse-event reporting and identity or purity characterization are likely to be the most useful, since those are the areas where agency reviewers raised concerns.
Sources
- US Food and Drug Administration. “July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.” Docket FDA-2026-N-2979. fda.gov
- McDermott Will & Schulte. “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting.” Client alert, July 27, 2026.
- Holland & Knight. “FDA Advisory Committee Endorses Compounding of Certain Peptides.” August 2026.
- Latham & Watkins. “FDA on Peptides: A New Landscape for Compounders.” 2026.
- Orrick. “FDA Peptide Compounding Vote: What to Watch at the July PCAC Meeting.” July 2026.
- Sheppard Mullin. “What to Watch: Status Update on Peptide Regulation.” June 2026.